13 completed, 5 active not recruiting, 2 recruiting, 2 terminated. 24 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 13, Active not recruiting 5, Recruiting 2, Terminated 2, Withdrawn 2 |
| Phase 1 | 1 | Completed 1 |
Follow ETOP IBCSG Partners Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 Tarlatamab - Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 48 | 2026-04-15 | 2026-09-21 |
| AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC Sotorasib, Lenvatinib - Metastatic Non Small Cell Lung Cancer, KRAS G12C | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2025-03-01 | 2024-11-20 | |
| Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer Brigatinib, Durvalumab - NSCLC, Stage III, ALK-rearrangement | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2024-06-07 | 2024-10-08 | |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer Giredestrant, Triptorelin, Anastrozole - Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 231 | 2024-01-23 | 2026-02-24 |
| Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC Niraparib - SCLC,Extensive Stage, SLFN11-positive | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 44 | 2023-12-20 | 2026-05-29 |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status Adagrasib - NSCLC Stage IV, KRAS P.G12C | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 68 | 2023-06-12 | 2026-09-03 |
| Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Amivantamab, Lazertinib, Zirabev - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 60 | 2023-03-27 | 2026-01-21 |
| Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) Osimertinib, Stereotactic Body Radiation Therapy (SBRT) - NSCLC Stage IV, EGFR Gene Mutation | Phase 2 | Terminated | ETOP IBCSG Partners Foundation | 6 | 2022-08-04 | 2024-06-28 |
| ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma Atezolizumab, Bevacizumab, Carboplatin - EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 95 | 2020-09-29 | 2026-07-29 |
| Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC Durvalumab, Carboplatin, Paclitaxel - Non-small Cell Lung Cancer, Stage IV | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 96 | 2019-11-19 | 2026-10-05 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide - Breast Cancer Stage II, Breast Cancer Stage III | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 366 | 2019-06-14 | 2026-05-12 |
| To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) Paclitaxel, Trastuzumab, Pertuzumab - Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 147 | 2019-04-16 | 2026-10-21 |
| ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Alectinib - Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic | Phase 2 | Terminated | ETOP IBCSG Partners Foundation | 14 | 2018-11-06 | 2026-07-21 |
| Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Nivolumab - Thymoma Type B3, Thymic Carcinoma | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 55 | 2018-04-11 | 2026-05-15 |
| MEtronomic TrEatment Option in Advanced bReast cAncer Paclitaxel, Cyclophosphamide, Capecitabine - Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 140 | 2017-09-13 | 2024-02-26 |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M Osimertinib, Bevacizumab - Non Small Cell Lung Cancer Metastatic | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 155 | 2017-05-31 | 2026-08-26 |
| Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer Palbociclib, Fulvestrant - Metastatic Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 124 | 2016-08-30 | 2026-08-26 |
| Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Ipilimumab, Nivolumab - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 222 | 2015-12-18 | 2026-08-24 |
| NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma Nivolumab - Non-small Cell Lung Cancer Stage III | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 94 | 2015-11-25 | 2026-08-24 |
| Afatinib in NSCLC With HER2 Mutation Afatinib - NSCLC | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 13 | 2015-09-16 | 2026-08-26 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (9) · Breast Neoplasms (6) · Neoplasm Metastasis (4) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Lung Neoplasms (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1) · Thymoma (1)
Paclitaxel (5) · Bevacizumab (3) · Nivolumab (3) · palbociclib (3) · Carboplatin (2) · Letrozole (2) · Radiosurgery (2) · Triptorelin Pamoate (2) · durvalumab (2) · osimertinib (2) · 130-nm albumin-bound paclitaxel (1) · AC protocol (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Anastrozole (1)
Spain (19) · Italy (17) · Switzerland (17) · France (12) · Belgium (10) · Germany (9) · Netherlands (9) · United Kingdom (8) · Ireland (6) · Poland (3) · Singapore (3) · South Korea (3) · Australia (2) · Austria (2) · Greece (2)
Dirk De Ruysscher, MD PhD (2) · Elisabetta Munzone, MD (2) · Matthias Guckenberger, MD-PhD (2) · Rafal Dziadziuszko, MD (2) · Solange Peters, MD PhD (2) · Alessandra Gennari, MD (1) · Alfredo Addeo (1) · Egbert F. Smith, MD-PhD (1) · Enriqueta Felip, MD-PhD (1) · Etienne Brain, MD (1) · Federico Capuzzo, MD (1) · Guy Jerusalem, MD, PhD (1) · Hans Wildiers, MD, PhD (1) · Isabelle Schmitt-Opitz, MD (1)
PMID 22327623, PMID 23814043, PMID 25349307, PMID 27544060, PMID 28408243, PMID 28447912, PMID 29228091, PMID 30589600, PMID 30765258, PMID 34393061, PMID 35172272, PMID 37440239, PMID 40023017, PMID 42833236
2014 (3), 2016 (2), 2017 (2), 2015 (1), 2018 (1)